Get my own profile
Public access
View all17 articles
2 articles
available
not available
Based on funding mandates
Co-authors
- Simon CookSignalling Programme, The Babraham InstituteVerified email at babraham.ac.uk
- Matthew SaleUCSFVerified email at ucsf.edu
- Julie WickendenPost-doctoral Researcher, University of CambridgeVerified email at horizondiscovery.com
- Scott NewmanGeneDxVerified email at sema4.com
- Sylvie GuichardDirector Translational Science Forma TherapeuticsVerified email at astrazeneca.com
- Eileen WhiteRutgers UniversityVerified email at cinj.rutgers.edu
- Martin TurnerThe Babraham Institute, Cambridge, CB22 3AT, UK.Verified email at babraham.ac.uk
- Manuel D Diaz-MunozATIP-Avenir Group Leader, Toulouse Institute for Infectious and Inflammatory DiseasesVerified email at inserm.fr
- Anne CorcoranBabraham InstituteVerified email at babraham.ac.uk
- Pamela LochheadBabraham InstituteVerified email at babraham.ac.uk
- Timothy PERRENConsultant Medical Oncologist, Leeds teaching Hospitals NHS TrustVerified email at leeds.ac.uk
- Tom DunkleyLab Head Mass Spectrometry, Roche Innovation Center Basel @ pREDVerified email at roche.com
- Kevin HudsonAstraZenecaVerified email at astrazeneca.com
- Martin McMahonCumming-Presidential Professor of Cancer Biology, Huntsman Cancer Institute, Univ. of UtahVerified email at hci.utah.edu
- John LunecNewcastle UniversityVerified email at ncl.ac.uk
- Duncan JodrellProfessor of Cancer Therapeutics, University of CambridgeVerified email at cam.ac.uk
- Mark CockerillCancer Research UK